Medicamen Biotech Ltd (MEDICAMEQ) is currently trading at 352.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Medicamen Biotech Limited (MBL) is a research-driven pharmaceutical company focusing on developing, manufacturing, and marketing finished dosage formulations globally. MBL has a strong presence in over 40 countries and is a key player in the Indian oncology segment with its own sales force and branding team. The company operates three advanced pharmaceutical manufacturing facilities in India, capable of producing a wide range of therapeutic categories. MBL has undertaken strategic expansions, including substantial investments in manufacturing infrastructure, to meet increasing demand in both domestic and international markets. The acquisition of OPAL Pharmaceuticals Pty Ltd enhanced MBL's capabilities and market reach, particularly in the oncology product line.

Over the past 52 weeks, Medicamen Biotech Ltd has traded between a low of ₹292.50 and a high of ₹560.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Medicamen Biotech Ltd has a market capitalization of approximately 496.53. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Medicamen Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 46.40 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Medicamen Biotech Ltd (MEDICAMEQ) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 496.53 Cr, Medicamen Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Medicamen Biotech Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Medicamen Biotech Ltd is 46.40. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Medicamen Biotech Ltd pays dividends with a current dividend yield of 0.26%. Dividend-paying stocks may provide periodic income in addition to potential long-term capital appreciation.

Key risks associated with Medicamen Biotech Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.